Nifedipine Medication Market, By Dosage Form (Tablets, Extended-release Tablets, Capsules, and Others (Sublingual tablets/spray, Patches and Others)), By Indication (Hypertension, Angina Pectoris, Raynaud\\\'s Phenomenon, and Others (Pre-term labor, vasos

Nifedipine Medication Market, By Dosage Form (Tablets, Extended-release Tablets, Capsules, and Others (Sublingual tablets/spray, Patches and Others)), By Indication (Hypertension, Angina Pectoris, Raynaud\\\'s Phenomenon, and Others (Pre-term labor, vasospastic conditions and Others)), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Nifedipine is a calcium channel blocker medication which is used for treating high blood pressure and chest pain caused by angina. Calcium channel blockers work by relaxing muscles in artery walls and increasing the supply of blood and oxygen to the heart. Nifedipine was first approved for medical use in 1983. It works by blocking calcium channels in heart and artery muscle cells. This helps blood vessels dilate, thus lowering blood pressure and reducing strain on the heart. It comes in both short-acting and long-acting tablet formulations and has proven effective for millions worldwide in controlling blood pressure and reducing chest pain.

Market Dynamics:

A growing number of people suffering from hypertension and cardiovascular illnesses and increasing aging population are major factors expected to drive growth of the global nifedipine medication market during the forecast period.

Moreover, market players are indulged in launching new products for nifedipine and this is expected to increase the growth of the global nifedipine market, over the forecast period. For instance, on September 18, 2019, AVET Pharmaceuticals, a developer of generic medicines, launched nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia and adds to Avet’s robust portfolio of generic oral solid products.

However, patent expiration, regulatory challenges, adverse effects, availability of alternative treatments, shifting treatment paradigms, pricing pressures are expected to hamper the growth of the global nifedipine medication market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global nifedipine medication market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nifedipine medication market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, Lupin Limited , Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (a Novartis division) Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd, and Apotex
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nifedipine medication market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nifedipine medication market

Global Nifedipine Medication Market Detailed Segmentation:

• By Dosage Form:
• Tablets
• Extended-release Tablets
• Capsules
• Others (Sublingual tablets/spray, Patches and Others)
• By Indication:
• Hypertension
• Angina Pectoris
• Raynaud's Phenomenon
• Others (Pre-term labor, vasospastic conditions and Others)
• By Distribution Channel:
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles:
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sanofi S.A.
• Johnson & Johnson
• GlaxoSmithKline plc
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Sandoz International GmbH (a Novartis division)
• Dr. Reddy's Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Apotex Inc.